HomeTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Nakaraang pagsara
$3.72
Sakop ng araw
$3.62 - $3.76
Sakop ng taon
$3.03 - $14.80
Market cap
3.44M USD
Average na Volume
28.06K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 666.00K | -53.88% |
Net na kita | -790.00K | 59.90% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -666.00K | 65.46% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.83M | -58.12% |
Kabuuang asset | 2.92M | -63.85% |
Kabuuang sagutin | 483.00K | -66.55% |
Kabuuang equity | 2.44M | — |
Natitirang share | 914.23K | — |
Presyo para makapag-book | 1.39 | — |
Return on assets | -51.03% | — |
Return on capital | -58.72% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -790.00K | 59.90% |
Cash mula sa mga operasyon | -506.00K | 77.47% |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | -62.00K | -115.27% |
Net change in cash | -568.00K | 57.49% |
Malayang cash flow | -193.25K | 80.89% |
Tungkol
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Itinatag
1991
Headquarters
Website
Mga Empleyado
4
